Relation of Serum Level of Lipocalin 2 to Her2/neu in Women with Breast Cancer

Authors

  • Atheer R. Atia1 , Salam S. Ahmed2

DOI:

https://doi.org/10.37506/ijfmt.v14i3.10805

Keywords:

Breast cancer, lipocalin 2, and Her2/neu

Abstract

Background: Breast cancer is the most common type of cancer worldwide, being one of the leading

causes morbidity in the female.(1) Lipocalin is a neutrophil gelatinase-associated lipocalin (NGAL) or

lipocalin 2 that is a 25 KDa glycoprotein, which was originally identified as a covalent complex with matrix

metalloproteinase-9 (MMP-9) in human neutrophil.(2) Lipocalin acts as bone-derived hormone which crosses

the blood brain barrier (BBB) and acts on the hypothalamus in the brain. The human epidermal growth

factor receptor 2 (HER-2/neu), has shown to have a prognostic value for the treatment with the monoclonal

antibody in breast cancer.(3)

Material and Method: This is a cross sectional, hospital based study. This study was carried out at the

Oncology Center in Kirkuk City-Iraq from the 1st of November 2018 to the end of June 2019. Forty-two

women with breast cancer were considered as a study group. Forty-four apparently healthy women without

breast cancer (relative of patients) and with a negative family history for the first and second degree relatives

of breast cancer were consider as a control group, their ages were from 23 to 70 year. By using a sterile

disposable syringe 10 mls of venous blood sample was drawn from each woman at morning and was kept in

a plain tube and allowed to clot at room temperature, then each sample was centrifuged at 6000 rpm to obtain

serum. Serum of the patients and controls had assay for lipocalin 2 and Her2/neu by ELISA.

Results: The mean serum level of lipocalin 2 was significantly elevated in breast cancer women compared

to control women (62.77 ± 6.1 and 23.98 ± 5.9 ng/l) respectively at a P value of 0.001. This study also

reveals that the mean serum level of Her2/neu was higher in breast cancer women (33.96 ± 2.7 ng/ml) as

compared with the control group (9.76 ± 1.6 ng/ml). This result was highly significant at a P value of 0.001.

This study found that there was a moderate positive correlation between lipocalin with Her2/neu in breast

cancer women (R: 0.33), which means that lipocalin 2 was proportionally elevated with increasing of Her2/

neu level.

Conclusion: This study reveals that there was a significant positive correlation between lipocalin and Her2/

neu in breast cancer women, the r value was 0.33.

Author Biography

  • Atheer R. Atia1 , Salam S. Ahmed2

    1 Asst. Lec. Kirkuk General Hospital, Kirkuk Governorate/Iraq, 2Prof Dr. Professor of Clinical & Medical

    Biochemistry–A General Pediatrician, College of Medicine–University of Tikrit/Iraq

Downloads

Published

2020-07-30

How to Cite

Relation of Serum Level of Lipocalin 2 to Her2/neu in Women with Breast Cancer. (2020). Indian Journal of Forensic Medicine & Toxicology, 14(3), 2456-2462. https://doi.org/10.37506/ijfmt.v14i3.10805